BISPECIFIC ANTIBODY

The present invention addresses the problem of providing a novel drug for preventing, inhibiting the progression of, inhibiting the recurrence of, or treating autoimmune diseases and the like. As the result of diligent research, the inventors of the present invention, focusing on PD-1/CD3 bispecific antibodies as substances capable of solving said problem, confirmed that said antibodies can be used in preparations for alleviating the occurrence of adverse reactions known as infusion reactions or cytokine release syndrome. The inventors also confirmed that said bispecific antibodies have the characteristic of permitting interaction between PD-1 and its ligand PD-L1, and discovered that such a characteristic contributes to potentiating or sustaining prevention of, inhibition of the progression of, inhibition of the recurrence of, or therapeutic effects upon autoimmune diseases.